Tofacitinib: A Promising Therapeutic Option for Refractory Pityriasis Rubra Pilaris—A Case Report

ABSTRACT Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder that can severely impact the quality of life in patients, particularly when presenting in chronic or refractory form. Emerging evidence suggests that JAK inhibitors may offer a potential treatment option. Here, we present a...

Full description

Bibliographic Details
Published in:	Clinical Case Reports
Main Authors:	Mahsa Taremi, Nikoo Mozafari
Format:	Article
Language:	English
Published:	Wiley 2025-10-01
Subjects:	JAK inhibitors pityriasis rubra pilaris tofacitinib upadacitinib
Online Access:	https://doi.org/10.1002/ccr3.71232

Similar Items

Tofacitinib for Pityriasis Rubra Pilaris: A Case Report
by: Tan H, et al.
Published: (2024-08-01)

Refractory pityriasis rubra pilaris treated with abrocitinib
by: Filip Rob
Published: (2025-01-01)

Juvenil Pityriasis Rubra Pilaris: A Case Report
by: M. Emin YANIK et al., et al.
Published: (2010-05-01)

Ustekinumab as an Alternative Treatment Option for Chronic Pityriasis Rubra Pilaris
by: Mudit Chowdhary, et al.
Published: (2015-03-01)

Pityriasis rubra pilaris (Devergie's disease): clinical case
by: Galkina ЕМ, et al.
Published: (2016-09-01)

Pityriasis rubra pilaris secondary to viral infection
by: Kacper Pawlik, et al.
Published: (2024-02-01)

Management of refractory pityriasis rubra pilaris: challenges and solutions
by: Moretta G, et al.
Published: (2017-11-01)

Pitiriasis rubra pilaris asociada a artritis reumatoidea: Presentación de 1 caso
by: Marisela Moreira Preciado, et al.
Published: (2000-09-01)

Pityriasis Rubra Pilaris refractory to ustekinumab successfully treated with guselkumab
by: João Teixeira, et al.
Published: (2024-09-01)

Pityriasis rubra pilaris: A review
by: Vladimir P. Adaskevich
Published: (2024-10-01)

Drug-related pityriasis rubra pilaris with acantholysis
by: Gajinov Zorica T., et al.
Published: (2013-01-01)

A case of paraneoplastic pityriasis rubra pilaris
by: Nina Mehta, BS, et al.
Published: (2023-09-01)

Uncommon Presentation of Pityriasis Rubra Pilaris of the Scalp: Clinical, Trichoscopic, and Histopathologic Features and Review of the Literature
by: Michela Starace, et al.
Published: (2024-11-01)

Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl
by: Lauren Bonomo, BA, et al.
Published: (2018-03-01)

Efficacy of Bimekizumab in the Management of Refractory Erythrodermic Pityriasis Rubra Pilaris: Clinical Insights
by: Sofia Theotokoglou, et al.
Published: (2025-07-01)

A clinical case of pityriasis rubra pilaris - juvenile type
by: Bahrambek Mukhamedov, et al.
Published: (2023-06-01)

Acute pityriasis rubra pilaris triggered by COVID‐19
by: Diego Soto‐García, et al.
Published: (2024-03-01)

Long-Standing Remission After Tildrakizumab Treatment in a Case of Refractory Type I Pityriasis Rubra Pilaris in a Breast Cancer Patient
by: Di Lernia V, et al.
Published: (2024-10-01)

Rethinking pityriasis rubra pilaris as a paraneoplastic syndrome: Two cases of pityriasis rubra pilaris with concomitant underlying malignancy
by: Anna E. Davis, BS, et al.
Published: (2023-02-01)

Pityriasis rubra pilaris developing after COVID-19
by: Mine Müjde Kuş, et al.
Published: (2022-03-01)

Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris
by: Luca Potestio, et al.
Published: (2024-07-01)

Risankizumab for the treatment of pityriasis rubra pilaris postanaplastic large cell lymphoma
by: Georgia Koroneos, BSc, MD, et al.
Published: (2024-06-01)

Recalcitrant pityriasis rubra pilaris in a Middle Eastern patient and arguments for early anti‐IL‐23 targeting
by: Mohammed N. Al‐Abdulla, et al.
Published: (2024-09-01)

Case Report: Successful treatment of a novel variant of CARD14-mutated juvenile Pityriasis rubra pilaris with ixekizumab
by: Laura Millak, et al.
Published: (2025-07-01)

Pityriasis rubra pilaris following COVID-19 vaccination successfully treated with ixekizumab
by: Patricia Zhao, BS, et al.
Published: (2023-05-01)

Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—A systematic review
by: Xiaofang Zhang, et al.
Published: (2025-02-01)

Sezary syndrome initially presenting as pityriasis rubra pilaris: Clinicopathologic study of 3 cases
by: Mouaz Alsawas, MD, MSc, et al.
Published: (2024-02-01)

Are Blue Straggler Stars a Hidden Clue? Intriguing Discovery in Pityriasis Rubra Pilaris Under UV-Induced Fluorescence Dermoscopy
by: Divya Madonna Dsouza, et al.
Published: (2025-07-01)

Case report: Area of focus of management of severe pityriasis rubra pilaris by dose optimization of adalimumab biosimilar in combination with acitretin and montelukast
by: Kristine Heidemeyer, et al.
Published: (2023-11-01)

Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children
by: Marta Kołt-Kamińska, et al.
Published: (2023-09-01)

The comprehensive impact of pityriasis rubra pilaris on physical symptoms, mental health, and activities of daily living: A mixed methods study
by: Rose C. Velasco, et al.
Published: (2023-03-01)

Nuclear Factor κB Activation in a Type V Pityriasis Rubra Pilaris Patient Harboring Multiple CARD14 Variants
by: Judit Danis, et al.
Published: (2018-07-01)

Effective Treatment of Prurigo Nodularis With Oral Tofacitinib: A Case Report
by: Nikoo Mozafari
Published: (2025-03-01)

بروز بیماری پیترازیس روبرا پیلاریس به علت قرار گرفتن در معرض سنگ دولومیت
by: Fariba Iraji, et al.
Published: (2015-03-01)

Dermatosis discoide facial. Serie de 13 casos
by: B. Butrón-Bris, et al.
Published: (2025-06-01)

Ustekinumab-Induced Fatal Acute Heart Failure in a Young Female: A Case Report
by: Mahmoud Abdelnabi, et al.
Published: (2022-07-01)

Guselkumab - In Psoriasis and Beyond
by: Aditya Kumar Bubna, et al.
Published: (2024-07-01)

Utility of dermoscopy in the diagnosis of erythroderma: A cross-sectional study
by: Jayati Batra, et al.
Published: (2023-01-01)

Effective Treatment of Livedoid Vasculopathy With Oral Tofacitinib
by: Parvin Mansouri, et al.
Published: (2025-06-01)

Atopic dermatitis: Tofacitinib, an option for refractory disease
by: Sineida Berbert Ferreira, et al.
Published: (2020-12-01)